Business Context and Reporting Period
Company: Rocket Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 26, 2018
Reporting Period: Single event date (November 26, 2018)
Context: The registrant is an emerging growth company incorporated in Delaware. This filing serves as a Regulation FD disclosure regarding the release of an updated corporate presentation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material financial changes or operational updates are detailed within the text of this Form 8-K. The sole material event reported is the availability of an updated corporate presentation on the company's website.
Guidance, Outlook, and Risks
Management Commentary: The company made an updated corporate presentation available on November 26, 2018. The content of this presentation is furnished as Exhibit 99.1.
Legal Disclaimer: In accordance with General Instruction B.2 of Form 8-K, the information in this report and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. It shall not be incorporated by reference into any registration statement unless expressly set forth by specific reference.
Investor Verification Checklist
- Review Exhibit 99.1 (Rocket Pharmaceuticals, Inc. Presentation, dated November 26, 2018) for specific financial data, pipeline updates, and strategic outlook not included in this summary.
- Verify the company's status as an emerging growth company and any associated election regarding extended transition periods for accounting standards.
- Confirm that the corporate presentation has been accessed via the company's official website as referenced in the filing.